真实的你
发表于 2025-3-28 17:18:17
Treatment: Rituximab,ients, those with relapsing, recrudescent, or unresponsive disease are likely to respond to rituximab infusions. Patients who are intolerant of steroids are also likely to respond, and rituximab is effective as single-agent therapy. This chapter reviews the available evidence regarding rituximab the
Folklore
发表于 2025-3-28 21:54:08
http://reply.papertrans.cn/47/4611/461100/461100_42.png
remission
发表于 2025-3-29 02:03:55
Pathology,fficult because lesions of IgG4-SC are present in the deep part of the bile duct wall. Liver biopsies may obtain peripheral portal tracts packed with lymphoplasmacytic infiltration, but characteristic bile duct lesions are absent. Thus, the appropriate clinical setting is necessary to make a diagnos
Peak-Bone-Mass
发表于 2025-3-29 03:32:24
http://reply.papertrans.cn/47/4611/461100/461100_44.png
在前面
发表于 2025-3-29 09:20:50
http://reply.papertrans.cn/47/4611/461100/461100_45.png
gait-cycle
发表于 2025-3-29 11:58:09
http://reply.papertrans.cn/47/4611/461100/461100_46.png
裂缝
发表于 2025-3-29 16:12:23
Treatment: Immunomodulatory Drugs,t for IgG4-SC is corticosteroid therapy. Unfortunately, despite the high initial remission rates, 15–60% of patients will develop disease relapse either after cessation of steroid therapy or during the weaning of the steroid dose . In Japan, to prevent relapses in type 1 AIP (including IgG4-SC)
蜡烛
发表于 2025-3-29 20:22:03
http://reply.papertrans.cn/47/4611/461100/461100_48.png
pessimism
发表于 2025-3-30 00:31:46
http://reply.papertrans.cn/47/4611/461100/461100_49.png
嘲弄
发表于 2025-3-30 06:11:29
Itaru Naitoh,Takahiro Nakazawa,Hirotaka Ohara,Takashi Joh